背景:超声特征有助于区分良性和恶性肿块,其中一些包含在超声(US)评分中。这项工作的主要目的是描述某些难以分类的附件肿块的超声特征,并根据最常用的美国分数进行分析。
方法:在接受手术的女性中,附件病变的回顾性研究很难通过US评分进行分类。分析了超声特征,根据超声医师的主观评估(SA)和其他美国评分(IOTA简单规则风险评估-SRRA,ADNEX型号,带和不带CA125和O-RADS)。
结果:共研究了133个附件肿块(良性:66.2%,n:88;恶性:33.8%,n:45)在平均年龄为56.5±7.8岁的女性样本中。在所有病例中通过SA鉴定恶性病变。卵巢交界性肿瘤(n:13)并不总是通过某些US评分检测到(SRRA:76.9%,无CA125的ADNEX模型:76.9%和84.6%)也没有浆液性癌(n:19)(SRRA:89.5%),透明细胞癌(n:9)(SRRA:66.7%)或子宫内膜样癌(n:4)(无CA125的ADNEX模型:75.0%)。虽然大多数畸胎瘤和浆液性囊腺瘤已被正确区分,其他良性病变由于存在实性区域或乳头而被错误分类。纤维瘤(n:13)通过SA(23.1%的恶性肿瘤)得到更好的鉴定,但与其他美国得分(SRRA:69.2%,ADNEX型号不带和带CA125:84.6%和69.2%,O-RADS:53.8%)。囊腺纤维瘤(n:10)难以通过除SRRA(SA:70.0%,SRRA:20.0%,不带和带CA125的ADNEX型号:60.0%和50.0%,O-RADS:90.0%)。粘液性囊腺瘤(n:12)在所有US评分中,在超过15%的病例中被误诊为恶性(SA:33.3%,SRRA:16.7%,ADNEX型号不带和带CA125:16.7%和16.7%,O-RADS:41.7%)。Brenner肿瘤也很难使用所有评分进行分类。
结论:一些恶性肿块(交界性卵巢肿瘤,浆液性癌,透明细胞癌,子宫内膜样癌)并不总是通过US评分检测到。纤维瘤,囊腺纤维瘤,一些粘液性囊腺瘤和Brenner肿瘤可能存在实体成分/乳头,可能导致与恶性病变混淆。大多数畸胎瘤和浆液性囊腺瘤通常被正确分类。
BACKGROUND: Ultrasound features help to differentiate benign from malignant masses, and some of them are included in the ultrasound (US) scores. The main aim of this work is to describe the ultrasound features of certain adnexal masses of difficult classification and to analyse them according to the most frequently used US scores.
METHODS: Retrospective studies of adnexal lesions are difficult to classify by US scores in women undergoing surgery. Ultrasound characteristics were analysed, and masses were classified according to the Subjective Assessment of the ultrasonographer (SA) and other US scores (IOTA Simple Rules Risk Assessment-SRRA, ADNEX model with and without CA125 and O-RADS).
RESULTS: A total of 133 adnexal masses were studied (benign: 66.2%, n:88; malignant: 33.8%, n:45) in a sample of women with mean age 56.5 ± 7.8 years. Malignant lesions were identified by SA in all cases. Borderline ovarian tumors (n:13) were not always detected by some US scores (SRRA: 76.9%, ADNEX model without and with CA125: 76.9% and 84.6%) nor were serous carcinoma (n:19) (SRRA: 89.5%), clear cell carcinoma (n:9) (SRRA: 66.7%) or endometrioid carcinoma (n:4) (ADNEX model without CA125: 75.0%). While most teratomas and serous cystadenomas have been correctly differentiated, other benign lesions were misclassified because of the presence of solid areas or papillae. Fibromas (n:13) were better identified by SA (23.1% malignancy), but worse with the other US scores (SRRA: 69.2%, ADNEX model without and with CA125: 84.6% and 69.2%, O-RADS: 53.8%). Cystoadenofibromas (n:10) were difficult to distinguish from malignant masses via all scores except SRRA (SA: 70.0%, SRRA: 20.0%, ADNEX model without and with CA125: 60.0% and 50.0%, O-RADS: 90.0%). Mucinous cystadenomas (n:12) were misdiagnosed as malignant in more than 15% of the cases in all US scores (SA: 33.3%, SRRA: 16.7%, ADNEX model without and with CA125: 16.7% and 16.7%, O-RADS:41.7%). Brenner tumors are also difficult to classify using all scores.
CONCLUSIONS: Some malignant masses (borderline ovarian tumors, serous carcinoma, clear cell carcinoma, endometrioid carcinomas) are not always detected by US scores. Fibromas, cystoadenofibromas, some mucinous cystadenomas and Brenner tumors may present solid components/papillae that may induce confusion with malignant lesions. Most teratomas and serous cystadenomas are usually correctly classified.